Table 4 Comparison between PHEO and PGL, and between non-metastatic and metastatic PPGL.
PHEO | PGL | Non-metastatic PPGL | Metastatic PPGL | ||||
|---|---|---|---|---|---|---|---|
Variable | Overall, N = 541 | N = 46 (85%)1 | N = 8 (15%)1 | p-value 2 | N = 47 (87%)1 | N = 7 (13%)1 | p-value 2 |
Age | 50.50 [36.00, 58.00] | 50.50 [36.00, 56.75] | 53.00 [36.75, 64.00] | 0.584 | 50.00 [35.50, 58.50] | 53.00 [43.00, 54.50] | 0.887 |
Sex | 0.706 | 0.047 | |||||
Female | 28 (51.85%) | 23 (50.00%) | 5 (62.50%) | 27 (57.45%) | 1 (14.29%) | ||
Male | 26 (48.15%) | 23 (50.00%) | 3 (37.50%) | 20 (42.55%) | 6 (85.71%) | ||
Tumor size (cm) | 4.85 [3.43, 6.08] | 4.75 [3.33, 6.18] | 5.10 [4.80, 5.23] | 0.817 | 4.80 [3.35, 5.50] | 8.70 [5.05, 10.70] | 0.058 |
KS | 0.491 | 0.750 | |||||
0 | 3 (5.56%) | 3 (6.52%) | 0 (0.00%) | 3 (6.38%) | 0 (0.00%) | ||
1 | 5 (9.26%) | 4 (8.70%) | 1 (12.50%) | 5 (10.64%) | 0 (0.00%) | ||
2 | 14 (25.93%) | 10 (21.74%) | 4 (50.00%) | 11 (23.40%) | 3 (42.86%) | ||
3 | 21 (38.89%) | 19 (41.30%) | 2 (25.00%) | 19 (40.43%) | 2 (28.57%) | ||
4 | 11 (20.37%) | 10 (21.74%) | 1 (12.50%) | 9 (19.15%) | 2 (28.57%) | ||
TBR | 2.10 [1.33, 3.43] | 2.19 [1.38, 3.73] | 1.29 [1.04, 2.05] | 0.141 | 2.08 [1.28, 3.35] | 2.25 [1.45, 4.88] | 0.562 |
